Get the Stockscreener App
3.88
1.04%
0.04
After Hours:
3.77
-0.11
-2.84%
Senti Biosciences Inc stock is traded at $3.88, with a volume of 8,164.
It is up +1.04% in the last 24 hours and up +0.39% over the past month.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
See More
Previous Close:
$3.84
Open:
$3.81
24h Volume:
8,164
Relative Volume:
0.21
Market Cap:
$85.29M
Revenue:
$1.79M
Net Income/Loss:
$-70.90M
P/E Ratio:
-0.2497
EPS:
-15.54
Net Cash Flow:
$-34.95M
1W Performance:
+34.72%
1M Performance:
+0.39%
6M Performance:
+80.47%
1Y Performance:
+25.16%
1-Day Range:
$3.4984
$3.91
1-Week Range:
$2.96
$3.91
52-Week Range:
$1.5201
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Inc
Sector
Industry
Phone
(650) 382-3281
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
3.88 | 85.29M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Stock (SNTI) Latest News
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment - The Manila Times
Gene Circuit Pioneer Senti Bio Opens Access: CEO & CMO Host Live Investor Q&A - Stock Titan
Senti Biosciences (SNTI) Stock Price, News & Analysis - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire
Senti Bio appoints new scientific advisory board member By Investing.com - Investing.com South Africa
Senti Bio appoints new scientific advisory board member - Investing.com
Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D. - GlobeNewswire
Senti Bio Joins Webull Corporate Connect Service Platform - The Manila Times
Senti Biosciences joins Webull’s Corporate Connect Service By Investing.com - Investing.com Australia
Senti Biosciences joins Webull’s Corporate Connect Service - Investing.com
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Manila Times
Groundbreaking Clinical Trial Data: SENTI-202 Shows Promise for Hard-to-Treat Blood Cancer - Stock Titan
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire
Virtu Financial LLC Acquires Shares of 13,356 Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World
Senti Biosciences Files Shelf for 52.9 Million Shares - MarketScreener
Senti Biosciences Files For Shelf Of Up To 52.9 Mln Shares Of Common Stock By Selling StockholdersSEC Filing - Marketscreener.com
Senti Bio Reports Promising Trial Results and Financial Growth - TipRanks
Senti Biosciences Inc. (SNTI) reports earnings - Quartz
Senti Biosciences, Inc. SEC 10-K Report - TradingView
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights - The Manila Times
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and ... - The Bakersfield Californian
Rigetti Computing Stock Falls Despite Nvidia Quantum Day. Should You Buy the Dip? - The Globe and Mail
Hogs Trading Mixed on Thursday - The Globe and Mail
Will Senti Biosciences Turn Heads In 2025? - RTTNews
Senti Bio Appoints Feng Hsiung to Board of Directors - The Manila Times
Senti Bio appoints new board member, grants stock options - Investing.com
Senti Bio Appoints Feng Hsiung To Board Of Directors -March 13, 2025 at 05:31 pm EDT - Marketscreener.com
KKR Partner Joins Senti Bio Board as Company Bolsters Leadership Team - Stock Titan
Senti Biosciences Expands Board with New Appointment - TipRanks
Senti Biosciences Announces Board Changes and Equity Plan Update - Investing.com
Senti Biosciences secures stockholder nods for equity plans By Investing.com - Investing.com Australia
Senti Biosciences secures stockholder nods for equity plans - Investing.com
Comparing Senti Biosciences (NASDAQ:SNTI) and Windtree Therapeutics (NASDAQ:WINT) - Defense World
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
Lindsay Androski named CEO of Arbutus - biocentury.com
Senti Biosciences Appoints New CFO Jay Cross - TipRanks
Senti Bio appoints Jay Cross as CFO - TipRanks
Senti Biosciences expands leadership with new CFO and SVP By Investing.com - Investing.com Canada
Senti Biosciences expands leadership with new CFO and SVP - Investing.com India
Senti Bio Strengthens Leadership Team with Strategic Hires - The Manila Times
Senti Biosciences (NASDAQ:SNTI) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire
Senti Biosciences CEO Timothy Lu sells shares worth $18,338 - MSN
Senti Biosciences executive sells $6,074 in stock - MSN
Senti Biosciences Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):